This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Elsevier's MEDalternatives Offers Additional Cost Saving Options For Payers And Members

TAMPA, Florida, February 6, 2013 /PRNewswire/ --

New comprehensive resource for drug therapy options and costs helps health plan payers and members save on drug spend with information on alternative therapies

Elsevier's Gold Standard, a leading drug information provider, today announced the launch of the MEDalternatives™ database, a comprehensive resource for drug therapy options designed to give health plans and their members additional drug cost savings options through access to information on alternative therapies. MEDalternatives uses only evidence-based alternatives that have comparable or better efficacy and safety, compared to current prescriptions.

MEDalternatives covers a broad range of health conditions and the widest scope of medications, including a complete offering of drugs, drug classes, and product formulations. It returns alternatives within the class of the patient's current medication and across classes, including both generics and brands, and also provides therapeutically appropriate choices among subclasses of drugs.

MEDalternatives includes complete dosing options to ensure accurate comparisons in daily/weekly regimens and monthly/yearly costs, including those for in-store purchase versus mail-order delivery.

"MEDalternatives delivers a unique payer solution that identifies safe and cost- effective medication alternatives for achieving therapy compliance and prescription cost savings," said Marianne Messer, President, Elsevier's Gold Standard. "This will help our payer and PBM clients reduce prescription drug costs, particularly those who have already maximized their brand-to-generic switching, and improve medication adherence."

MEDalternatives helps:
  • Simplify drug regimens and drive down costs for payers and patients
  • Improve compliance for healthier and less expensive outcomes
  • Payers control prescription costs by offering therapeutic alternatives on brand-to-brand drugs, as well as brand-to-generic drugs
  • Payers educate providers and members on where savings can be attained on drugs
  • PBMs (Pharmacy Benefit Managers) enforce formulary compliance
  • Help providers identify alternative therapies to reduce costs
  • Guide consumers toward more affordable, safer and more effective medication options
  • Involve consumers in these choices, knowing that cost and convenience play a central role in adherence to treatment
  • Prepare consumers to discuss options with their healthcare providers
  • Boost patients' satisfaction with their drug benefits

MEDalternatives is derived from the most technologically sophisticated drug database available today and will easily integrate within and across diverse healthcare systems.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs